Marta Byrska-Bishop

Marta Byrska-Bishop

Auto-generated profile, based on publicly available information

Marta Byrska-Bishop

New York Genome Center, New York, NY, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2021 in Science
Verified
Journal Article
Closed access
PDF file
PEPeter Ebert
Peter Ebert
PAPeter A. Audano
Peter A. Audano
QZQihui Zhu
Qihui Zhu
BRBernardo Rodriguez-Martin
Bernardo Rodriguez-Martin
DPDavid Porubsky
David Porubsky
FMF. Kumara Eugene Mastrorosa
F. Kumara Eugene Mastrorosa
Resolving genomic structural variation: Many human genomes have been reported using short-read technology, but it is difficult to resolve structural variants (SVs) using these data. These genomes thus lack comprehensive comparisons among individuals and populations. Ebertet al.used long-read structural variation calling across 64 human genomes representing diverse populations and developed new methods for variant discovery. This approach allowed the authors to increase the number of confirmed SVs and to describe the patterns of variation across populations. From this dataset, they identified quantitative trait loci affected by these SVs and determined how they may affect gene expression and potentially explain genome-wide association study hits. This information provides insights into patterns of normal human genetic variation and generates reference genomes that better represent the diversity of our species.Science, this issue p.eabf7117

9 September 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JFJonathan Foox
Jonathan Foox
STScott W. Tighe
Scott W. Tighe
CNCharles M. Nicolet
Charles M. Nicolet
JZJustin M. Zook
Justin M. Zook
MBMarta Byrska-Bishop
Marta Byrska-Bishop
Christopher MasonChristopher Mason
Christopher Mason

26 July 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AWAmy B. Wilfert
Amy B. Wilfert
TTTychele N. Turner
Tychele N. Turner
SMShwetha C. Murali
Shwetha C. Murali
PHPingHsun Hsieh
PingHsun Hsieh
ASArvis Sulovari
Arvis Sulovari
FMF. Kumara Eugene Mastrorosa
F. Kumara Eugene Mastrorosa

7 February 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
MBMarta Byrska-Bishop
Marta Byrska-Bishop
UEUday S. Evani
Uday S. Evani
XZXuefang Zhao
Xuefang Zhao
ABAnna O. Basile
Anna O. Basile
HAHaley J. Abel
Haley J. Abel
MZMichael C. Zody
Michael C. Zody
SUMMARY: The 1000 Genomes Project (1kGP) is the largest fully open resource of whole genome sequencing (WGS) data consented for public distribution of raw sequence data without access or use restrictions. The final release of the 1kGP included 2,504 unrelated samples from 26 populations and was based primarily on low coverage WGS. Here, we present a new, high coverage 3,202-sample WGS 1kGP resource, sequenced to a targeted depth of 30X using the Illumina NovaSeq 6000 system, which now includes 602 complete trios. We performed SNV/INDEL calling against the GRCh38 reference using GATK’s HaplotypeCaller, and generated a comprehensive set of SVs by integrating multiple analytic methods through a sophisticated machine learning model. We make all the data generated as part of this project publicly available and we envision it to become the new de facto public resource for the worldwide genomics and genetics community.

25 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JWJustin Wagner
Justin Wagner
NONathan D Olson
Nathan D Olson
LHLindsay Harris
Lindsay Harris
JMJennifer McDaniel
Jennifer McDaniel
ZKZiad Khan
Ziad Khan
JZJustin M. Zook
Justin M. Zook
Summary: Genome in a Bottle (GIAB) benchmarks have been widely used to help validate clinical sequencing pipelines and develop new variant calling and sequencing methods. Here, we use accurate linked reads and long reads to expand the prior benchmarks in 7 samples to include difficult-to-map regions and segmental duplications that are not readily accessible to short reads. Our new benchmark adds more than 300,000 SNVs, 50,000 indels, and 16 % new exonic variants, many in challenging, clinically relevant genes not previously covered (e.g., PMS2 ). For HG002, we include 92% of the autosomal GRCh38 assembly, while excluding problematic regions for benchmarking small variants (e.g., copy number variants and reference errors) that should not have been in the previous version, which included 85% of GRCh38. By including difficult-to-map regions, this benchmark identifies eight times more false negatives in a short read variant call set relative to our previous benchmark.We have demonstrated the utility of this benchmark to reliably identify false positives and false negatives across technologies in more challenging regions, which enables continued technology and bioinformatics development.

26 December 2022 in Bioinformatics
Verified
Journal Article
Open access
PDF file
YNYonghyun Nam
Yonghyun Nam
SJSANG-HYUK JUNG
SANG-HYUK JUNG
JYJae-Seung Yun
Jae-Seung Yun
VSVivek Sriram
Vivek Sriram
PSPankhuri Singhal
Pankhuri Singhal
DKDokyoon Kim
Dokyoon Kim
Understanding comorbidity is essential for disease prevention, treatment and prognosis. In particular, insight into which pairs of diseases are likely or unlikely to co-occur may help elucidate the potential relationships between complex diseases. Here, we introduce the use of an inter-disease interactivity network to discover/prioritize comorbidities. Specifically, we determine disease associations by accounting for the direction of effects of genetic components shared between diseases, and categorize those associations as synergistic or antagonistic. We further develop a comorbidity scoring algorithm to predict whether diseases are more or less likely to co-occur in the presence of a given index disease. This algorithm can handle networks that incorporate relationships with opposite signs. We finally investigate inter-disease associations among 427 phenotypes in UK Biobank PheWAS data and predict the priority of comorbid diseases. The predicted comorbidities were verified using the UK Biobank inpatient electronic health records. Our findings demonstrate that considering the interaction of phenotype associations might be helpful in better predicting comorbidity. The source code and data of this study are available at https://github.com/dokyoonkimlab/DiseaseInteractiveNetwork. Supplementary data are available at Bioinformatics online.